Medivir AB has begun a Phase IIa trial in patients infected with chronic genotype 1 hepatitis C to evaluate the efficacy, safety and tolerability of a 12-week combination therapy of simeprevir, TMC647055 and JNJ56914845, a NS5A replication complex inhibitor. Approximately 40 patients will be enrolled in this open-label study to assess the efficacy, safety and tolerability of the combination regimen. The trial will evaluate genotype 1a and 1b HCV-infected patients who are either treatment-naïve ...